x
ServiziMenu principaleHome
Home > Faculty
Print

Faculty and Panel Members

Coordinating Chair

   

Fatima CardosoFatima Cardoso
Breast Unit
Champalimaud Clinical Center
Lisbon, PT

  
 

Chairs

 

 
Eric WinerEric P. Winer
Breast Oncology Center
Dana-Farber Cancer Institute
Boston, US
Larry NortonLarry Norton
Breast Cancer Programs
Memorial Sloan-Kettering Cancer Centre
New York, US
Alberto CostaAlberto Costa
European School of Oncology
Milan IT and Bellinzona, CH

Co-Chairs

 

 
Elzbieta SenkusGiuseppe Curigliano
European Institute of Oncology
Milan, IT
Evi PapadopoulosShirley A. Mertz
Metastatic Breast Cancer Network,
Inverness, US
 

Scientific Committee Members

 
Elzbieta SenkusKaren Gelmon
BC Cancer Agency
Vancouver, CA



Elzbieta SenkusChristoph Thomssen
Martin-Luther-Universität
Klinikum Kröllwitz
Halle (Saale), DE

Fabrice AndréFrédérique Penault-Llorca
Jean Perrin Centre
Comprehensive Cancer Centre
Clermont-Ferrand, FR
Elzbieta SenkusElzbieta Senkus
Medical University of Gdansk
Gdansk, PL

Faculty 

Matti S. Aapro
Breast Center, Clinique de Genolier, CH

Bertha Aguilar Lopez
Salvati, Mexico City, MX

Fabrice André
Department of Medical Oncology, Gustave Roussy Institute, Villejuif, FR

Carlos H. Barrios
Department of Medicine, PUCRS School of Medicine, Porto Alegre, BR

Jonas Bergh
Department of Oncology-Pathology, Karolinska Institute, Stockholm, SE

Gouri S. Bhattacharyya
Department of Medical Oncology, Salt Lake City Medical Centre, Kolkata, IN

Laura Biganzoli
Department of Medical Oncology, Sandro Pitigliani Oncology Centre, Prato, IT

Christine B. Boers-Doets
Department of Medical Strategy, CancerMed, Wormer, NL and Department of Adverse Event Research & Valorisation, Impaqtt Foundation, Wormer, NL

Fran Boyle
The Pam McLean Centre, Royal North Shore Hospital, St. Leonards, AU

Anna Cabanes
Susan G. Komen, Washington, US

Maria João Cardoso
Breast Unit, Champalimaud Cancer Center and Mama Help, Lisbon, PT

Lisa A. Carey
Department of Hematology and Oncology, UNC Lineberger Comprehensive Cancer Center, North Carolina, US

Javier Cortés
IOB Institute of Oncology, Madrid and Barcelona, ES

Carsten Denkert
Department of Pathology, Marburg University, Marburg , DE

Nagi S. El Saghir
NK Basile Cancer Institute, American University of Beirut Medical Center, Beirut, LB

Mona Elzayat
Europa Donna, the European Breast Cancer Coalition, Vienna, AT

Alexandru Eniu
Department of Breast Tumors, Cancer Institute "I. Chiricuta", Cluj-Napoca, RO and European School of Oncology, Bellinzona, CH

Lesley Fallowfield
Sussex Health Outcomes Research & Education in Cancer, Brighton & Sussex Medical School, University of Sussex, Brighton, UK

Prudence A. Francis
Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, AU

Joseph Gligorov
Breast Cancer Expert Center, University Cancer Institute APHP.6 - Sorbonne University, Paris, France

Uwe Güth
Breast Centre, Zurich, CH

Renate Haidinger
Brustkrebs Deutschland e.V., Munich, DE

Nadia Harbeck
Breast Centre, University of Munich, Munich, DE

Xichun Hu
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, CN

Bella Kaufman
Oncology Institute, Sheba Medical Center, Tel Hashomer, IL

Ranjit Kaur
Breast Cancer Welfare Association Malaysia, Petaling Jaya, MY

Belinda E. Kiely
NHMRC Clinical Trials Centre, Sydney Medical School, Sydney, AU

Sung-Bae Kim
Asan Medical Centre, University of Ulsan College of Medicine, Department of Oncology, Seoul, KR

Frédéric E. Lecouvet
Dept of Radiology, Centre du Cancer and Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels, BE

Nancy U. Lin
Breast Oncology Center, Dana-Farber Cancer Institute, Boston, US

Sabine Linn
The Netherlands Cancer Institute, Amsterdam, NL

Paul Mainwaring
Department of Oncology, Canossa Hospital, Oxley, AU

Claire Myerson
Patient Advocate, Oxford, UK

Gertrude Nakigudde
Uganda Women's Cancer Support Organisation, Kampala, UG

Silvia Neciosup
Department of Medical Oncology, National Institute of Neoplastic Diseases, Lima, PE

Birgitte V. Offersen
Department of Oncology, Aarhus University Hospital, Aarhus, DK

Shinji Ohno
Breast Oncology Centre, Cancer Institute Hospital, Tokyo, JP

Olivia Pagani
Breast Unit, Oncology Institute of Southern Switzerland, Bellinzona, CH

Shani Paluch-Shimon
Oncology Institute, Shaare Zedek Medical Centre, Jerusalem, IL

Kirsten Pilatti
Breast Cancer Network Australia, Camberwell, AU

Aleix Prat
Hospital Clínic of Barcelona, University of Barcelona, Barcelona, ES

Gabriella Pravettoni
European Institute of Oncology, Milan, IT

Catherine Priestley
Breast Cancer Care & Breast Cancer Now, London, UK

Joana Ribeiro
Breast Unit, Champalimaud Clinical Center, Lisbon, PT

Shawna Rich-Ginsberg
Rethink Breast Cancer, Toronto, CA

Hope S. Rugo
Breast Oncology and Clinical Trials Education, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US

Peter Schmid
Centre for Experimental Cancer Medicine, Barts Cancer Institute, London, UK

George W. Sledge
Division of Oncology, Stanford School of Medicine, Stanford, US

Luzia Travado
Breast Unit, Champalimaud Clinical Center, Lisbon, PT

Andrew Tutt
Division of Breast Cancer Research and Breast Cancer Now Toby Robins Research Centre, Institute of Cancer Research and Guy’s Hospital King’s College London, UK

Daniel A. Vorobiof
Belong.Life, New York, US

Theresa Wiseman
The Royal Marsden Hospital NHS Foundation Trust, London, UK

Binghe Xu, Department of Medical Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN

Consensus Panellist

Matti S. Aapro, CH
Fabrice André, FR
Carlos H. Barrios, BR
Jonas Bergh, SE
Gouri S. Bhattacharyya, IN
Laura Biganzoli, IT
Fatima Cardoso, PT
Maria João Cardoso, PT
Lisa A. Carey, US
Javier Cortés, ES
Alberto Costa, IT/CH
Giuseppe Curigliano, IT
Nagi S. El Saghir, LB
Mona Elzayat, AT
Alexandru Eniu, RO
Lesley Fallowfield, UK
Prudence A. Francis, AU
Karen Gelmon, CA
Joseph Gligorov, FR
Renate Haidinger, DE
Nadia Harbeck, DE
Xichun Hu, CN
Bella Kaufman, IL
Ranjit Kaur, MY
Belinda E. Kiely, AU
Sung-Bae Kim, KR
Nancy U. Lin, US
Shirley A. Mertz, US
Silvia Neciosup, PE
Larry Norton, US
Birgitte V. Offersen, DK
Shinji Ohno, JP
Olivia Pagani, CH
Shani Paluch-Shimon, IL
Frédérique Penault-Llorca,FR
Aleix Prat, ES
Hope S. Rugo, US
Elzbieta Senkus, PL
George W. Sledge, US
Christoph Thomssen, DE
Daniel A. Vorobiof, US
Theresa Wiseman, UK
Eric P. Winer, US
Binghe Xu, CN

Breast Cancer Patient Advocacy Committee

Coordinator
Fatima Cardoso, ABC Global Alliance, Lisbon, PT

Bertha Aguilar Lopez, Salvati, Mexico City, MX
Karen Benn, Europa Donna - the European Breast Cancer Coalition, Milan, IT
Anna Cabanes, Susan G. Komen, Washington, US
Maria João Cardoso, Mama Help, Lisbon, PT
Renate Haidinger, Brustkrebs Deutschland e.V., Munich, DE
Ranjit Kaur, Breast Cancer Welfare Association Malaysia, Petaling Jaya, MY
Shirley A. Mertz, Metastatic Breast Cancer Network, Inverness, US
Gertrude Nakigudde, Uganda Women's Cancer Support Organisation, Kampala, UG
Kirsten Pilatti, Breast Cancer Network Australia, Camberwell, AU
Catherine Priestley, Breast Cancer Care & Breast Cancer Now, London, UK
Shawna Rich-Ginsberg, Rethink Breast Cancer, Toronto, CA

Disclosure of conflict of interest

Faculty members have been asked to disclose any potential conflict of interest in relation to their participation in the conference. Potential conflict of interest are considered any of the following:

- Any financial interest in or arrangement with a company whose products or services are discussed in the lecture or that might be considered as part of the consensus process.

- Any financial interest in or arrangement with a competing company.

- Any other financial relationship, direct or indirect, or other situations that might raise the question of bias in the work presenter or in the participation in the consensus process, including
  pertinent commercial or other sources of funding for the speaker or panellist or for the associated department or organisation, personal relationships or direct academic competition.

ABC5 Chairs, Co-Chairs, Scientific Committee Members, faculty and panel members

Matti S. Aapro: Receipt of consultation fees: Amgen, BMS, Celgene, Clinigen, Eisai, Genomic Health, GSK, Helsinn, Hospira, JnJ, Novartis, Merck, Merck Serono, Mundipharma, Pfizer, Pierre Fabre, Roche, Sandoz, Tesaro, Tevam Vifor, G1 Therapeutics, Lilly. Receipt of honoraria for symposia lectures: Amgen, Bayer Schering, Cephalon, Chugai, Eisai, Genomic Health, GSK, Helsinn, Hospira, Ipsen, JnJ Ortho Biotech, Kyowa Hakko Kirin, Merck, Merck Serono, Mundipharma, Novartis, Pfizer, Pierre Fabre, Roche, Sandoz, Sanofi, Tesaro, Taiho, Tevam Vifor, G1 Therapeutics, Lilly.
Bertha Aguilar Lopez: No significant relationships.
Fabrice André: Not received.
Carlos H. Barrios: No significant relationships.
Jonas Bergh: Receipt of grants/research supports: grants from Amgen, AstraZeneca, Bayer, Merck, Pfizer, Roche, Sanofi-Aventis to Karolinska institute and University hospital. No personal payments. Other support: Payment from UpToDate to Asklepios Medicine HB for a chapter on breast cancer prediction.
Gouri Shankar Bhattacharyya: No significant relationships.
Laura Biganzoli: Receipt of grants/research supports: Celgene, Genomic Health, Novartis. Receipt of honoraria or consultation fees: AstraZeneca, Celgene, Eisai, Genomic Health, Ipsen, Lilly, Novartis, Pfizer, Pierre Fabre, Roche
Christine B. Boers-Doets: Receipt of grants/research supports: Amgen, AstraZeneca, Bayer, Eusa Pharma, GSK, Merck, Novartis, Pfizer, Roche. Receipt of honoraria or consultation fees: Amgen, AstraZeneca, Baxalta, Bayer, Becton, Dickinson & Company (BD), Boehringer Ingelheim, Bristol-Myers Squibb, Eusa Pharma, Galera, GSK, Helsinn, Ipsen, Lilly, Lifestream Pharma, Merck, MSD, Nordic Pharma,
Novartis, Pfizer, Roche, Sanofi Aventis, Takeda.
Fran Boyle: Not received.
Anna Cabanes: Receipt of grants/research supports: Pfizer. Participation in a sponsored speakers’ bureau: AstraZeneca.
Fatima Cardoso: Receipt of honoraria or consultation fees: Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, GSK, Macrogenics, Medscape, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre Fabre, prIME Oncology, Roche, Sanofi, Seattle Genetics, Teva.
Maria-João Cardoso: No significant relationships.
Lisa A. Carey: No significant relationships.
Javier Cortés: Receipt of grants/research supports: Research funding to the Institution: Roche, Ariad pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer healthcare, Eisai, F.Hoffman-La Roche, Guardanth health, Merck Sharp&Dohme, Pfizer, Piqur Therapeutics, Puma C, Queen Mary University of London.
Receipt of honoraria or consultation fees: HONORARIA: Roche, Novartis, Celgene, Eisai, Pfizer, Samsung. ADVISOR: Roche, Celgene, Cellestia, AstraZeneca, Biothera Pharmaceutical, Merus, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex. Stock shareholder: MedSIR.
Alberto Costa: No significant relationships.
Giuseppe Curigliano: Receipt of honoraria or consultation fees: Roche, Pfizer, Lilly, Novartis, SEAGEN. Participation in a sponsored speakers’ bureau: SEAGEN, Pfizer, Lilly, Novartis.
Carsten Denkert: Receipt of grants/research support: Teva, Novartis, Pfizer, Roche, Amgen. Receipt of honoraria or consultation fees: MSD, Daiichi. Stock shareholder: Sividon Diagnostics.
Nagi S. El Saghir: Receipt of grants/research supports: Novartis (Institution). Receipt of honoraria or consultation fees: Novartis, Roche, Pfizer, Lilly, AstraZeneca.
Mona Elzayet: Support: Advisory activity: Novartis, Roche.
Alexandru Eniu: Receipt of grants/research support: Astra Zeneca, Roche, Celltrion, Pfizer, Novartis.
Lesley Fallowfield: Receipt of grants/research support: BMS, GSK, Myriad, Novartis.
Receipt of honoraria or consultation fees: BMS, AstraZeneca, Teva, Novartis, Eisai, Takeda, Pfizer, Lilly, Genomic Health, Myriad.
Prudence A. Francis: Receipt of honoraria or consultation fees: AstraZeneca, Novartis. Pfizer travel for lecture.
Karen Gelmon: Receipt of grants/research support: AstraZeneca, Pfizer, BMS. Receipt of honoraria or consultation fees: Pfizer, AstraZeneca, Novartis, Nanostring, Merck, Mylan, Genomic Health, Roche, BMS.
Joseph Gligorov: Receipt of grants/research supports: Amgen, Eisai, Genomic Health, Novartis, Pfizer, Roche Genentech. Receipt of honoraria or consultation fees: Daiichi, Eisai, Genomic Health, Ipsen, Macrogenics, MSD, Mylan, Novartis, Onxeo, Pfizer, Roche Genentech. Participation in a sponsored speakers’ bureau: Eisai, Genomic Health, Ipsen, Novartis, Pfizer, Roche Genentech.
Uwe Güth: No significant relationships.
Renate Haidinger: No significant relationships.
Nadia Harbeck: Receipt of honoraria or consultation fees: Amgen, AstraZeneca, Celgene, Daiichi-Sakyo, Lilly, MSD, Novartis, Odonate, Pfizer, Roche, Sandoz/Hexal, Seattle Genetics.
Xichun Hu: No significant relationships.
Bella Kaufman: Not received.
Ranjit Kaur: Receipt of grants/research supports: Pfizer Malaysia.
Belinda E. Kiely: Receipt of grants/research support: Roche-advisory board and educational presentations, fees paid to me. Novartis advisory board and educational presentations, fees paid to me. Other support: Roche – travel and meeting expenses (San Antonio Breast Cancer Symposium 2017).
Sung-Bae Kim: Receipt of grants/research support: Novartis, Sanofi-genzyme, Dongkook Ltd.
Frédéric E. Lecouvet: Not received.
Nancy U. Lin: Receipt of grants/research support: Genentech, Seattle Genetics. Receipt of honoraria or consultation fees: Seattle Genetics, Daiichi, Puma.
Sabine Linn: Receipt of grants/research supports: Institutional research grants from Agendia, Amgen, AstraZeneca, Eurocept-pharmaceuticals, Genentech, Novartis, Pfizer, Roche, Sanofi, and Tesaro
Receipt of honoraria or consultation fees: Institutional consultation fees from AstraZeneca, Bayer, IBM, Novartis, Pfizer, Roche. Other support (please specify): Pro bono scientific advisory board member for Cergentis, and Philips Health.
Paul Mainwaring: Receipt of honoraria or consultation fees: Pfizer, Janssen. Participation in a sponsored speakers’ bureau: Pfizer, Janssen. Stock shareholder: XING technologies P/L.
Shirley A. Mertz: Receipt of honoraria: Pfizer, Lilly.
Claire Myerson: No significant relationships.
Gertrude Nakigudde: No significant relationships.
Silvia Neciosup: Receipt of grants/research support: Roche, Pfizer, BMS, Novartis. Participation in a sponsored speakers’ bureau: Roche, Pfizer, BMS, Merck, Novartis.
Larry Norton: Honorariums (2018-2019): Sermonix Oncology Ad Board, Prime Oncology, Sarah Lawrence Lecture, Context Advisory Board, Oncology Pioneers Science Lecture Series, BCRF Programmatic Review Meeting, CSHL External Advisory Board Meeting.
Birgitte V. Offersen: No significant relationships.
Shinji Ohno: Receipt of grants/research support: Chugai, Eisai, Taiho, Daiichi-Sankyo. Participation in a sponsored speakers’ bureau: Chugai, AstraZeneca, Eisai, Taiho, Pfizer, Lilly.
Olivia Pagani: Participation in a sponsored speakers’ bureau: Takeda, Roche, Pfizer, Novartis, Lilly.
Shani Paluch-Shimon: Roche: Speakers bureau: honoraria, consultancy. Astra Zeneca: Speakers bureau, honoraria, consultancy. Novartis: Speakers bureau, honoraria, consultancy. Pfizer: Speakers bureau, honoraria, consultancy. Nanostring: Speakers bureau, honoraria. Teva: Speakers bureau, honoraria.
Frederique Penault-Llorca: Receipt of grants/research support: Roche. Receipt of honoraria or consultation fees: Roche, Puma, Pierre Fabre, Astra Zeneca.
Kristen Pilatti: Not received.
Aleix Prat: Personal financial interests Lecture fees: Roche, Pfizer, Novartis, Amgen, BMS and Daiichi Sankyo. Advisory role/consultancy: Roche, Pfizer, Novartis, Amgen, BMS, Puma and Oncolytics Biotech.
Institutional financial interests: Contracted research: Novartis, Nanostring, Roche and Boehringer. Lecture fees: Nanostring technologies. Clinical trials: Novartis, Roche, Boehringer, Daiichi Sankyo, Pfizer, Lilly and Amgen.
Leadership roles: Executive boards: Beast International Group (BIG) and SOLTI cooperative group. Patronage committee: SOLTI Foundation and Actitud Frente al Cáncer Foundation.
Gabriella Pravettoni: No significant relationships.
Catherine Priestly: No significant relationships.
Joana Ribeiro: Not received.
Shawna Rich-Ginsberg: No significant relationships.
Hope S. Rugo: Receipt of grants/research support: Pfizer, Merck, Novartis, Lilly, Genentech, OBI, Odonate, Daiichi, Eisai, Seattle Genetics, Macrogenetics and Immunomedics.
Peter Schmid: Receipt of grants/research supports: AstraZeneka, Roche, Grnentech, Oncogenex, Novartis, Astellas. Receipt of honoraria or consultation fees: Pfizer, AstraZeneca, Novartis, Roche, Merck, Boehringer Ingelheim, Bayer, Eisai, Celgene, Puma. Spouse/partner: Consulting Genentech/Roche.
Elzbieta Senkus: Receipt of honoraria or consultation fees: Amgen, AstraZeneca, Clinigen, Egis, Eli Lilly, Novartis, Pfizer, Pierre Fabre, Sandoz, Roche. Travel support: Amgen, AstraZeneca, Egis, Novartis, Pfizer, Roche.
George W. Sledge: Not received.
Christoph Thomssen: Not received.
Luzia Travado: Not received.
Andrew Tutt: Receipt of grants/research support: Astra Zeneca, Merck Serono, Medivation, Myriad Genetics. Receipt of honoraria or consultation fees: Pfizer, Astrazaenca, Merck, Vertex, Artois, Inbiomotion, Prime Oncology for education seminar. Stock shareholder: Stock option: InBioMotion – Rewards to inventors’ scheme: ICR – Astra Zeneca-PARP inhibitors.
Daniel A. Vorobiof: No significant relationships.
Eric P. Winer: Receipt of grants/research supports: Merck, Genentech/Roche. Receipt of honoraria or consultation fees: Carrick Therapeutics, Genentech/Roche, Genomic Health, GSK, Jounce, Leap, Lilly, Merck, Seattle Genetics. Research to institute: Genentech/Roche and Merck. Scientific advisory board: Leap.
Theresa Wiseman: Not received.
Binghe Xu: Not received.